U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1% on Monday.

Shares of Graham Corp (NYSE:GHM) fell sharply in pre-market trading after the company reported fourth-quarter financial results.

Graham reported quarterly earnings of 33 cents per share which beat the analyst consensus estimate of 32 cents per share. The company reported quarterly sales of $67.078 million which beat the analyst consensus estimate of $59.952 million.

Graham shares dipped 8.7% to $97.83 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• BitVentures Ltd – ADR (NASDAQ:BVC) shares declined 16.3% to $8.45 in pre-market trading.
• Telkom Indonesia (Persero) Tbk PT -ADR (NYSE:TLK) shares dipped 13.1% to $13.50 in pre-market trading following a 3% decline on Friday.
• Indaptus Therapeutics Inc (NASDAQ:INDP) fell 12.3% to $3.21 in pre-market trading after declining 23% on Friday.
• Appian Corp (NASDAQ:APPN) declined 8.7% to $22.57 in pre-market trading.
• Wix.Com Ltd (NASDAQ:WIX) fell 8.4% to $48.00 in pre-market trading.
• KB Financial Group Inc (NYSE:KB) fell 7% to $100.38 in pre-market trading.
• SuRo Capital Corp (NASDAQ:SSSS) slipped 6.3% to $12.87 in pre-market trading after declining 3% on Friday.
• Century Therapeutics Inc (NASDAQ:IPSC) shares fell 6.1% to $2.00 in pre-market trading after declining 3% on Friday.
• Amplitude Inc (NASDAQ:AMPL) declined 4.7% to $7.30 in pre-market trading.
• Icecure Medical Ltd (NASDAQ:ICCM) fell 4.5% to $4.17 in pre-market trading after dipping 16% on Friday. IceCure Medical recently announced a 1-for-30 reverse share split.
• Sibanye Stillwater Ltd (NYSE:SBSW) fell 4.3% to $9.69 in pre-market trading after dropping 9% on Friday.
• Roma Green Finance Ltd (NASDAQ:ROMA) declined 4.2% to $6.64 in pre-market trading. On March 30, the company announced a $100 million share buyback.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.